The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Double-Blinded Randomized Study of High-Dose Calcitriol Plus Docetaxel Compared With Placebo Plus Docetaxel in Androgen-Independent Prostate Cancer: A Report From the ASCENT Investigators
Open accessAbstract
Purpose: To compare the safety and activity of DN-101, a new high-dose oral formulation of calcitriol designed for cancer therapy, and docetaxel with placebo and docetaxel. Patients and Methods: Patients with progressive metastatic androgen-independent prostate cancer and adequate organ function received weekly docetaxel 36 mg/m 2 intravenously for 3 weeks of a 4-week cycle combined with either 45 μg DN-101 or placebo taken orally 1 day before docetaxel. The primary end point was prostate-specific antigen (PSA) response within 6 months of enrollment, defined as a 50% reduction confirmed at least 4 weeks later. Results: Two hundred fifty patients were randomly assigned. Baseline characteristics were similar in both arms. Within 6 months, PSA responses were seen in 58% in DN-101 patients and 49% in placebo patients (P = .16). Overall, PSA response rates were 63% (DN-101) and 52% (placebo), P = .07. Patients in the DN-101 group had a hazard ratio for death of 0.67 (P = .04) in a multivariate analysis that included baseline hemoglobin and performance status. Median survival has not been reached for the DN-101 arm and is estimated to be 24.5 months using the hazard ratio, compared with 16.4 months for placebo. Grade 3/4 adverse events occurred in 58% of DN-101 patients and in 70% of placebo-treated patients (P = .07). Most common grade 3/4 toxicities for DN-101 versus placebo were neutropenia (10% v 8%), fatigue (8% v 16%), infection (8% v 13%), and hyperglycemia (6% v 12%). Conclusion: This study suggests that DN-101 treatment was associated with improved survival, but this will require confirmation because survival was not a primary end point. The addition of weekly DN-101 did not increase the toxicity of weekly docetaxel.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735
Self-citationPetrylak, D. P., Tangen, C. M., Hussain, M. H. A., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D., Moinpour, C., Kohli, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041318 · Cited by 3,665
Self-citationSurrogate endpoints in clinical trials: Definition and operational criteria
Prentice, R. L. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080407 · Cited by 2,057
Bubley, G. J., Carducci, M., Dahut, W., Dawson, N., Daliani, D., Eisenberger, M., Figg, W. D., Freidlin, B., Halabi, S., Hudes, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3461 · Cited by 977
Self-citationCantorna, M. T., Munsick, C., Bemiss, C., & Mahon, B. D. (2000) · The Journal of Nutrition · doi:10.1093/jn/130.11.2648 · Cited by 494
Skowroński, R., Peehl, D. M., & Feldman, D. I. (1993) · Endocrinology · doi:10.1210/en.132.5.1952 · Cited by 494
Weekly High-Dose Calcitriol and Docetaxel in Metastatic Androgen-Independent Prostate Cancer
Beer, T. M., Eilers, K. M., Garzotto, M., Egorin, M. J., Lowe, B. A., & Henner, W. D. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.117 · Cited by 253
Self-citationGetzenberg, R. H., Light, B. W., Lapco, P. E., Konety, B. R., Nangia, A. K., Acierno, J. S., Dhir, R., Shurin, Z., Day, R. S., Trump, D. L., et al. (1997) · Urology · doi:10.1016/s0090-4295(97)00408-1 · Cited by 219
TREATMENT OF EARLY RECURRENT PROSTATE CANCER WITH 1,25-DIHYDROXYVITAMIN D3 (CALCITRIOL)
GROSS, C., STAMEY, T., HANCOCK, S., & FELDMAN, D. (1998) · Journal of Urology · doi:10.1016/s0022-5347(01)63236-1 · Cited by 206
Cited by
Vitamin D and Human Health: Lessons from Vitamin D Receptor Null Mice
Bouillon, R., Carmeliet, G., Verlinden, L., van Etten, E., Verstuyf, A., Luderer, H. F., Lieben, L., Mathieu, C., & Demay, M. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0004 · Cited by 1,783
Vitamin D signalling pathways in cancer: potential for anticancer therapeutics
Deeb, K. K., Trump, D. L., & Johnson, C. S. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2196 · Cited by 1,419
The role of vitamin D in reducing cancer risk and progression
Feldman, D., Krishnan, A. V., Swami, S., Giovannucci, E., & Feldman, B. J. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3691 · Cited by 1,311
Nonclassic Actions of Vitamin D
Bikle, D. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1454 · Cited by 974
Vitamin D, disease and therapeutic opportunities
Plum, L. A., & DeLuca, H. F. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3318 · Cited by 477
Metadata
- Authors
- Beer, T. M., Ryan, C. W., Venner, P. M., Petrylak, D. P., Chatta, G. S., Ruether, J. D., Redfern, C. H., Fehrenbacher, L., Saleh, M. N., Waterhouse, D. M., Carducci, M. A., Vicario, D., Dreicer, R., Higano, C. S., Ahmann, F. R., Chi, K. N., Henner, W. D., Arroyo, A., & Clow, F. W.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-02-09
- Volume
- 25
- Issue
- 6
- Pages
- 669-674
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2143289308
- Cited by
- 312
- References
- 22
- FWCI
- 37.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Double-Blinded Randomized Study of High-Dose Calcitriol Plus Docetaxel Compared With Placebo Plus Docetaxel in Androgen-Independent Prostate Cancer: A Report From the ASCENT Investigators. https://app.cochat.ai/papers/10.1200/jco.2006.06.8197
- The paper
- Beer, T. M., Ryan, C. W., Venner, P. M., Petrylak, D. P., Chatta, G. S., Ruether, J. D., Redfern, C. H., Fehrenbacher, L., Saleh, M. N., Waterhouse, D. M., Carducci, M. A., Vicario, D., Dreicer, R., Higano, C. S., Ahmann, F. R., Chi, K. N., Henner, W. D., Arroyo, A., & Clow, F. W. (2007). Double-Blinded Randomized Study of High-Dose Calcitriol Plus Docetaxel Compared With Placebo Plus Docetaxel in Androgen-Independent Prostate Cancer: A Report From the ASCENT Investigators. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2006.06.8197
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.